It is very uncertain whether levomepromazine changes leaving the study early ‐ short term ‐ due to lack of efficacy compared with atypical antipsychotics (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to patient deterioration compared with atypical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ lost to compared with atypical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to lack of efficacy compared with typical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with typical antipsychotics (low certainty).
It is very uncertain whether levomepromazine changes leaving the study early ‐ medium term ‐ any reason compared with typical antipsychotics (very low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ any reason compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ due to adverse events compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ long term ‐ lost to compared with typical antipsychotics (moderate certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ any reason compared with atypical antipsychotics (low certainty).
Levomepromazine showed no clear difference in leaving the study early ‐ short term ‐ due to adverse events compared with atypical antipsychotics (moderate certainty).
CLOZAPINE probably leads to lower relapse ‐ short term compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
CLOZAPINE probably leads to lower global impression: 1. Not clinically improved ‐ short term compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
CLOZAPINE showed no clear difference in adverse effects 1. Blood problems compared with TYPICAL ANTIPSYCHOTICS; GRADE not reported.
CLOZAPINE probably leads to higher adverse effects 4. Salivation ‐ too much compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
CLOZAPINE probably leads to higher adverse effects 5. Weight gain compared with TYPICAL ANTIPSYCHOTICS (moderate certainty).
CLOZAPINE showed no clear difference in unable to work compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).
CLOZAPINE probably leads to higher adverse effects: 1. Blood problems ‐ decreased white cell count compared with TYPICAL ANTIPSYCHOTICS ‐ OVERALL (moderate certainty).